Addressing barriers to initiation of insulin in patients with type 2 diabetes

Primary Care Diabetes

Volumn 4, Issue , 2010, Pages S11-S18

  Peyrot, Mark ^a,b   Rubin, Richard R ^b   Khunti, Kamlesh ^c  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Barrier resolution strategies; Insulin initiation; Patient barriers; Physician barriers

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ATTITUDE TO HEALTH; CLINICAL PRACTICE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; REVIEW;

ATTITUDE TO HEALTH; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN'S PRACTICE PATTERNS;

MLCS; MLOWN;

EID: 77954917386     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/S1751-9918(10)60004-6     Document Type: Article

References (44)

1. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
2. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J Med. 359 (2008), 1577–1589.
3. Ray, K.K., Seshasai, S.R., Wijesuriya, S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
4. Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006), 1963–1972.
5. Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R., Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999), 2005–2012.
6. Qayyum, R., Bolen, S., Maruthur, N., et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann. Intern. Med. 149 (2008), 549–559.
7. Rolla, A., Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am. J Med. 121 (2008), S9–S19.
8. Raskin, P., Efficacy and safety of insulin detemir, Endocrinol. Metab. Clin. North Am. 36:Suppl. 1 (2007), 21–32.
9. Kamal, A.D., Dixon, A.N., Bain, S.C., Safety and side effects of the insulin analogues. Expert Opin. Drug Saf. 5 (2006), 131–143.
10. Rubino, A., McQuay, L.J., Gough, S.C., et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet. Med. 24 (2007), 1412–1418.
11. Calvert, M.J., McManus, R.J., Freemantle, N., Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br. J Gen. Pract. 57 (2007), 455–460.
12. Nichols, G.A., Koo, Y.H., Shah, S.N., Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J. Gen. Intern. Med. 22 (2007), 453–458.
13. Valensi, P., Benroubi, M., Borzi, V., et al. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int. J Clin. Pract. 62 (2008), 1809–1819.
14. Korytkowski, M., When oral agents fail: practical barriers to starting insulin. Int. J Obes. Relat. Metab. Disord. 26:Suppl. 3 (2002), S18–S24.
15. Lustman, P.J., Clouse, R.E., Depression in diabetic patients: the relationship between mood and glycemic control. J. Diabetes Complications 19 (2005), 113–122.
16. Polonsky, W.H., Fisher, L., Guzman, S., et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 28 (2005), 2543–2545.
17. Polonsky, W.H., Fisher, L., Earles, J., et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 28 (2005), 626–631.
18. Brod, M., Kongso, J.H., Lessard, S., Christensen, T.L., Psychological insulin resistance: patient beliefs and implications for diabetes management. Qual. Life Res. 18 (2009), 23–32.
19. Peyrot, M., Psychological insulin resistance: overcoming barriers to insulin therapy. Pract. Diabetology 23 (2004), 6–12.
20. Peyrot, M., Rubin, R.R., Lauritzen, T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005), 2673–2679.
21. Diabetes Attitudes, Wishes and Needs (DAWN) study, Barriers to treatment. http://dawnstudy.com/documents/article_page/document/barriers.asp (accessed July 4, 2009).
22. Davis, S.N., Renda, S.M., Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ. 32:Suppl. 4 (2006), 146S–152S.
23. Polonsky, W.H., Anderson, B.J., Lohrer, P.A., et al. Insulin omission in women with IDDM. Diabetes Care 17 (1994), 1178–1185.
24. Hayes, R.P., Fitzgerald, J.T., Jacober, S.J., Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int. J Clin. Pract. 62 (2008), 860–868.
25. Nakar, S., Yitzhaki, G., Rosenberg, R., Vinker, S., Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J. Diabetes Complications 21 (2007), 220–226.
26. Grant, R.W., Wexler, D.J., Watson, A.J., et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 30 (2007), 1448–1453.
27. World Health Organization, Self-management support for chronic conditions using 5As. www.who.int/entity/diabetesactiononline/about/WHO%205A%20ppt.pdf (accessed July 4, 2009).
28. Peyrot, M., Rubin, R.R., Behavioral and psychosocial interventions in diabetes: a conceptual review. Diabetes Care 30 (2007), 2433–2440.
29. Orleans, C.T., Hutchinson, D., Tailoring nicotine addiction treatments for chemical dependency patients. J. Subst. Abuse Treat. 10 (1993), 197–208.
30. Snoek, F.J., Skovlund, S.E., Pouwer, F., Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual. Life Outcomes 5 (2007), 69–75.
31. Blonde, L., Merilainen, M., Karwe, V., et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study. Diabetes Obes. Metab. 11 (2009), 623–631.
32. Rubin, R.R., Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am. J Med. 118:Suppl. 5A (2005), 27S–34S.
33. Brunton, S., Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol. Ther. 10 (2008), 247–256.
34. Pfützner, A., FlexPen¯ for the delivery of insulin: accuracy, injection force and patient preference. Expert Rev. Med. Devices 6 (2009), 115–123.
35. Korytkowski, M., Bell, D., Jacobsen, C., Suwannasari, R., A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin. Ther. 25 (2003), 2836–2848.
36. Asakura, T., Seino, H., Nakano, R., et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol. Ther. 11 (2009), 657–661.
37. Renders, C.M., Valk, G.D., Griffin, S.J., et al. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database Syst. Rev., 2000 CD001481.
38. Siminerio, L.M., Funnell, M.M., Peyrot, M., Rubin, R.R., US nurses' perceptions of their role in diabetes care: results of the cross-national Diabetes Attitudes Wishes and Needs (DAWN) study. Diabetes Educ. 33 (2007), 152–162.
39. Piette, J.D., Weinberger, M., Kraemer, F.B., McPhee, S.J., Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs Health Care System: a randomized controlled trial. Diabetes Care 24 (2001), 202–208.
40. Davis, R.E., Lowes, L., Cradock, S., et al. Insulin initiation among adults and children with diabetes in the United Kingdom. Practical Diabetes Int. 23 (2006), 171–174.
41. Goyder, E.C., McNally, P.G., Drucquer, M., et al. Shifting of care for diabetes from secondary to primary care, 1990–5: review of general practices. BMJ 316 (1998), 1505–1506.
42. Khunti, K., Ganguli, S., Who looks after people with diabetes: primary or secondary care?. J. R. Soc. Med. 93 (2000), 183–186.
43. Khunti, K., Gadsby, R., Millett, C., et al. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet. Med. 24 (2007), 1436–1441.
44. Shojania, K.G., Ranji, S.R., McDonald, K.M., et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 296 (2006), 427–440.